On-Demand Webinar: Advancing Drug Development with ICP-MS: A Bioanalytical Perspective

The pharmaceutical industry faces increasing pressure to develop complex therapeutics under ever tighter regulatory scrutiny.

Elemental impurities can halt programmes late in development, uncharacterised bioanalytical risks may undermine safety assessments, and advanced modalities like metallodrugs demand tools capable of providing reliable data at trace levels. Traditional LC-MS workflows, while powerful, cannot fully address these challenges. Failure to adopt the right analytical strategies early on risks costly delays, failed regulatory submissions, or missed opportunities in competitive pipelines.

Watch our speakers Stuart McDougall, Principle Research Fellow, and Jonathan Charlton, Method Developer, as they demonstrate how Inductively Coupled Plasma Mass Spectrometry (ICP-MS) provides unmatched sensitivity and specificity for detecting and quantifying trace elements in complex biological matrices.

Key takeaways:

• Understand the unique capabilities of ICP-MS in bioanalysis and how it addresses limitations of traditional LC–MS approaches for trace element detection.
• Recognise key applications of ICP-MS in drug development, including pharmacokinetics of metallodrugs, endogenous biomarker measurement, and speciation analysis.
• Learn practical strategies for implementing ICP-MS workflows—covering sample preparation, matrix interference management, and regulatory-compliant method validation.
• Apply ICP-MS insights to strengthen bioanalytical strategies in your own organisation, reducing development risks, improving regulatory confidence, and accelerating project timelines.